EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop…
ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed…
ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a…
Initial clinical data demonstrate a very high 85% overall response rate in patients with metastatic castrate-resistant prostate cancer. FORT LAUDERDALE,…
Dr. Louis brings to TScan extensive experience in cell therapy, medical affairs, and clinical and commercial developmentWALTHAM, Mass., April 08,…
— Collaboration follows recent manufacturing/clinical process enhancements that have tripled monthly trial capacity — — Patient enrollment expected to be…
SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast…
PARSORTIX HER2 ASSAY SHOWCASED AT PRESTIGIOUS INTERNATIONAL CANCER CONFERENCECTC HER2 assay being developed for HER2 targeted drugs and antibody drug…
Toronto, Ontario--(Newsfile Corp. - April 7, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9) ("FSD Pharma" or…
SHANGHAI, China, April 07, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a…